
Atara Biotherapeutics, Inc.: quarterly results
Price
$7.70
November 13, 2026Market cap $118M
What Ploutos Investor adds for Atara Biotherapeutics
Part of Ploutos Investor, €9.99 a month
- The full history: 4 fiscal years, from 2022
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Notes on these figures
- The interest the company pays is far more than the debt we can read would cost, so part of its borrowing is missing from the figures. We leave out the debt, net cash, enterprise value and the multiples built on them.
Results, quarter by quarter
When the company put out each quarter's results (its 8-K, item 2.02), what they showed against the same quarter a year before, and how the stock moved on the first session after.
The first session after results
±11.5%average move, either way
1 times upof the last 43 times down
Largest: -25.7% on Jan 13, 2026 (Jan 12, 2026).
How the stock moved after each release
The close of the first session after the results against the close before them.
ATRA that sessionS&P 500 the same day
Every release
Revenue and diluted EPS of the quarter reported, with the change against the same quarter a year before.
- Q3 2026Stock, next session+1.6%
- –Stock, next session-7.8%
- –Stock, next session-10.9%
- –Stock, next session-25.7%
| Quarter | Released | Revenue | EPS | Stock, next session | S&P 500 | Filing |
|---|---|---|---|---|---|---|
| Q3 2026 | Nov 10, 2026after the close | $1.2M-64.6% | -$0.15 | +1.6% | +1.3% | 8-K |
| – | Aug 12, 2026after the close | – | – | -7.8% | +0.7% | 8-K |
| – | Mar 16, 2026after the close | – | – | -10.9% | +0.2% | 8-K |
| – | Jan 12, 2026after the close | – | – | -25.7% | -0.2% | 8-K |
Every release
ATRA's results days and the share's move after each, from Q4 2014 to Q3 2025, 49 more quarters
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 8 quarters.
and 44 more, back to Q4 2014
Times are the SEC's acceptance of the 8-K, in New York time: before 16:00 the market traded on it that day, after it the next day. A move on a results day has other causes too, and says nothing about the next one. A dash in a quarter's figures: the SEC's structured data does not have them.
The full analysis
What do Atara Biotherapeutics's filings show?
The results say what Atara Biotherapeutics reported. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.